Sanofi unveils plans for 170 million euros vaccine production facility

Sanofi is to spend 170 million euros ($201.5 million) on a vaccine manufacturing site in France.

The French pharma major says the investment in the Normandy facility will strengthen its position as one of the world's leading seasonal flu vaccine providers. It will allow the company to expand supply of VaxigripTetra to up to 70 countries in six continents.

Sanofi plans to complete the expansion by 2021, subject to relevant health authority approvals, and will begin producing vaccines in the facility in 2022.